Table 2 ICIs combined with traditional chemotherapies involving clinical trials against GCs

KEYNOTE-062 (NCT02494583)

Advanced GC/EGJC

Pembrolizumab + chemotherapy

PD-1

III

Pembrolizumab alone or plus chemotherapy was not superior to chemotherapy for the OS and PFS

Shitara et al. (2020) [19]

CheckMate-649 (NCT02872116)

Unresectable advanced GC

Nivolumab + chemotherapy

PD-1

III

Nivolumab plus chemotherapy presented superior OS compared to chemotherapy alone and reduce 20% of mortality

Moehler et al. (2020) [46]

NCT02937116

Locally advanced or metastatic GC

Sintilimab + CapeOx

PD-1

Ib

Sintilimab combined with CapeOx presented acceptable safety and promising efficacy

Jiang et al. (2020) [49]

NCT04065282

Advanced resectable GC/GEJ adenocarcinoma

Sintilimab + CapeOx

PD-1

II

Sintilimab plus oxaliplatin/capecitabine showed promising efficacy with encouraging pCR rate and good safety profile

Jiang et al. (2020) [50]

NCT03469557

Advanced GC

Toripalimab + CapeOx + tislelizumab + chemotherapy

PD-1

II

Tislelizumab plus chemotherapy presented durable responses with manageable tolerability

Xu et al. (2020) [51]

CS1001–101

Advanced GC/EGJC

CS1001 + XELOX

PD-1

I

CS1001 plus XELOX presented an ORR of 62% in patients with advanced GC

Shen et al. (2020) [52]

KEYNOTE-811 (NCT03615326)

Advanced GC/EGJC

Pembrolizumab with trastuzumab and chemotherapy

PD-1

III

Very preliminary data

Chung et al. (2021) [54]

NCT02954536

HER2-positive metastatic esophagogastric cancer.

Pembrolizumab with trastuzumab and chemotherapy

PD-1

II

pembrolizumab with trastuzumab and chemotherapy presented acceptable safety and promising efficacy against HER2+ cancer

Janjigian et al. (2020) [1]

UMIN-CTR

Advanced GC

Nivolumab with paclitaxel plus ramucirumab

PD-1

I/II

Nivolumab with paclitaxel plus ramucirumab presented promising antitumor activity with manageable toxicities

Nakajima et al. (2021) [55]